| Literature DB >> 27529064 |
Gyo-Nam Kim1, Mi-Rae Shin2, Sung Ho Shin2, Ah Reum Lee2, Joo Young Lee2, Bu-Il Seo2, Min Yeong Kim2, Tae Hoon Kim3, Jeong Sook Noh4, Man Hee Rhee5, Seong-Soo Roh2.
Abstract
Pancreatic lipase is the enzyme responsible for digestion and absorption of triglycerides, being its inhibition one of the widest studied methods used to determine the potential activity of natural products to inhibit dietary fat absorption. Decrease of energy intake from dietary fat through inhibition of this enzyme may be an excellent strategy to prevent and treat obesity. The inhibitory activity on pancreatic lipase enzyme of Diospyros kaki fruit and Citrus unshiu peel mixture extract (PCM) was evaluated in vitro and its antiobesity effects were studied based on the serum lipid parameters analysis from high-fat diet- (HFD-) fed mice in vivo. PCM was orally administered at a dose of 50 and 200 mg/kg body weight for 6 weeks. In addition, the activity of pancreatic lipase was assessed using orlistat (positive control). PCM exhibited inhibitory effect on lipase activity with IC50 value of 507.01 μg/mL. Moreover, serum triacylglycerol, total cholesterol levels, and visceral fat weight were significantly reduced compared to HFD control mice in PCM 200 mg/kg-treated mice (p < 0.05). These results suggest that PCM administration may be a novel potential antiobesity agent for reduction of fat absorption via inhibition of pancreatic lipase.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27529064 PMCID: PMC4978832 DOI: 10.1155/2016/1723042
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1DPPH radical scavenging activity (a, b) and ABTS radical scavenging activity (c, d). (a, c) Ascorbic acid and (b, d) PCM, Diospyros kaki fruit and Citrus unshiu peel mixture extract. Each experiment was run in triplicate. The ascorbic acid was used as standard sample.
Figure 2Inhibition of pancreatic lipase by PCM. Orlistat was used as positive control. PCM, Diospyros kaki fruit and Citrus unshiu peel mixture extract.
The effect of PCM on body weight and visceral fat weight.
| Group | Body weight | Visceral fat weight | ||
|---|---|---|---|---|
| Initial (g) | Final (g) | Change (g/6 weeks) | (g) | |
| Normal | 36.06 ± 0.96 | 47.92 ± 1.46 | 11.86 ± 1.00 | 24.1 ± 1.0 |
| HFD-fed mice | ||||
| Con | 37.67 ± 0.51 | 55.15 ± 1.78 | 17.48 ± 1.95 | 57.5 ± 1.5 |
| O | 36.71 ± 0.96 | 44.92 ± 1.62 | 8.21 ± 1.82 | 42.5 ± 2.8 |
| PCM50 | 37.18 ± 0.44 | 48.06 ± 0.17 | 10.88 ± 0.52 | 50.6 ± 3.2 |
| PCM200 | 36.93 ± 0.38 | 45.98 ± 0.94 | 9.05 ± 0.90 | 50.3 ± 2.3 |
Con, HFD control mice; O, orlistat 60 mg/kg-treated and HFD-fed mice; PCM50, PCM 50 mg/kg-treated and HFD-fed mice.
PCM 200, PCM 200 mg/kg-treated and HFD-fed mice. Data are the mean ± SEM, n = 8.
Significance: p < 0.05, p < 0.01, and p < 0.001 versus HFD control mice.
Figure 3Serum triglyceride, total cholesterol, HDL-cholesterol, and LDL-cholesterol levels. Con, HFD control mice; O, orlistat 60 mg/kg-treated and HFD-fed mice; PCM50, PCM 50 mg/kg-treated and HFD-fed mice. PCM200, PCM 200 mg/kg-treated and HFD-fed mice. Data are the mean ± SEM, n = 8. Significance: p < 0.05 and p < 0.01 versus HFD control mice.